THERAVANCE BIOPHARMA INC
NASDAQ: TBPH (Theravance Biopharma, Inc.)
最近更新时间: 1小时之前17.01
-0.01 (-0.06%)
| 前收盘价格 | 17.02 |
| 成交量 | 420,492 |
| 预期市盈率 (P/E Forward) | 9.73 |
| 价格/销量 (P/S) | 8.47 |
| 股市价格/股市净资产 (P/B) | 3.05 |
| 52周波幅 |
| 营业毛利率 | -89.38% |
| 营业利益率 (TTM) | -93.80% |
| 稀释每股收益 (EPS TTM) | -1.18 |
| 季度收入增长率 (YOY) | 6.10% |
| 总债务/股东权益 (D/E MRQ) | 29.01% |
| 流动比率 (MRQ) | 4.77 |
| 营业现金流 (OCF TTM) | 32.53 M |
| 杠杆自由现金流 (LFCF TTM) | 4.64 M |
| 资产报酬率 (ROA TTM) | -7.98% |
| 股东权益报酬率 (ROE TTM) | -31.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Theravance Biopharma, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.48% |
| 机构持股比例 | 91.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Jun 2026 | 9,212,252 |
| Weiss Asset Management Lp | 30 Jun 2026 | 7,457,060 |
| Newtyn Management, Llc | 30 Jun 2026 | 3,434,191 |
| Irenic Capital Management Lp | 30 Jun 2026 | 2,760,948 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合